We are building next-generation obesity treatments designed to sustain results, helping patients maintain progress over time through better biology and a more practical approach to real-world use.
The biology of the maintenance phase is fundamentally different from the biology of weight loss itself – we believe it deserves a different approach to best serve those who have achieved their weight-loss goals.
Every mechanism we pursue is anchored in validated biology. For our lead asset, ALV-100, human genetics shows that reducing GIPR activity can help protect against obesity, heart disease, and metabolic complications – through a pathway distinct from GLP-1.
ALV-100 is designed for quarterly maintenance dosing, a longer interval than other obesity assets in clinical development. That is not an incremental improvement. That is a fundamentally different life for patients.
ALV-100 plus two proprietary amylin programs, a selective injectable peptide and an oral small molecule, provide multiple shots on goal in the largest therapeutic market of the decade.
We have created a portfolio designed to support the desire of patients for quality weight loss, improved tolerability, and people-friendly dosing regimens. Enabling a positive patient experience places us on a clear path to transform the next generation of obesity therapy.
Every program starts with a molecule, and is carried forward by a team, a strategy, and an unrelenting commitment to patients.
Read about our scienceALV-100 is now enrolling for the Phase 1b weight loss study. Learn more about participation and eligibility.
Series A Investors
